Literature DB >> 35399312

Successful Response to Nivolumab Plus Ipilimumab Therapy in a Hemodialysis Patient With Metastatic Renal Cell Carcinoma.

Hiroshi Masuda1, Kosuke Mikami1, Kotaro Otsuka1, Kyokusin Hou1, Takahito Suyama1, Kazuhiro Araki1, Satoko Kojima1, Yukio Naya1.   

Abstract

Background/Aim: There are few reports about the administration of nivolumab plus ipilimumab to hemodialysis patients and their efficacy and safety have not been established yet. Case Report: A 74-year-old male, who was receiving hemodialysis, was presented with metastatic renal cell carcinoma (mRCC). Two years later, more metastases were found, hence, immunotherapy involving nivolumab plus ipilimumab was initiated. After two doses of immunotherapy, interstitial pneumonia was observed. Thus, steroid pulse therapy was administered immediately. Subsequently, computed tomography (CT) findings and symptoms improved markedly. One month later, a CT scan showed a nodular shadow and an air cavity. A fungal infection was strongly suspected, so an antifungal drug was administered.
Conclusion: Combination immunotherapy with nivolumab plus ipilimumab was demonstrated to be effective in a hemodialysis patient with mRCC. Copyright 2021, International Institute of Anticancer Research.

Entities:  

Keywords:  Fungal pneumonia; hemodialysis; immunotherapy; metastatic renal cell carcinoma

Year:  2021        PMID: 35399312      PMCID: PMC8962798          DOI: 10.21873/cdp.10028

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  10 in total

1.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

2.  [Pneumonia in maintenance hemodialysis patients: detection rate of causative organisms in sputum varies with time of sampling and quality].

Authors:  Koichi Sasaki; Satoshi Yamaguchi; Eriko Iwahashi; Taku Fujimoto; Satoshi Minami; Hiromi Rakugi; Yoshitaka Isaka; Kenji Yokoyama
Journal:  Nihon Jinzo Gakkai Shi       Date:  2014

3.  Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment.

Authors:  Tadashi Tabei; Ichiro Natsume; Kazuki Kobayashi
Journal:  Int J Urol       Date:  2017-07-21       Impact factor: 3.369

4.  Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Authors:  Omar Abdel-Rahman; Mona Fouad
Journal:  Ther Adv Respir Dis       Date:  2016-03-04       Impact factor: 4.031

Review 5.  Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.

Authors:  Ignacio Osmán-García; C Belen Congregado-Ruiz; Guillermo Lendínez-Cano; Cristina Baena-Villamarin; Jose Manuel Conde-Sanchez; Rafael Antonio Medina-López
Journal:  Urol Int       Date:  2020-01-08       Impact factor: 2.089

6.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

7.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Authors:  Myriam Delaunay; Jacques Cadranel; Amélie Lusque; Nicolas Meyer; Valérie Gounant; Denis Moro-Sibilot; Jean-Marie Michot; Judith Raimbourg; Nicolas Girard; Florian Guisier; David Planchard; Anne-Cécile Metivier; Pascale Tomasini; Eric Dansin; Maurice Pérol; Marion Campana; Oliver Gautschi; Martin Früh; Jean-David Fumet; Clarisse Audigier-Valette; Sébastien Couraud; Stéphane Dalle; Marie-Thérèse Leccia; Marion Jaffro; Samia Collot; Grégoire Prévot; Julie Milia; Julien Mazieres
Journal:  Eur Respir J       Date:  2017-08-10       Impact factor: 16.671

8.  Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis.

Authors:  Maria I Carlo; Darren R Feldman
Journal:  Eur Urol       Date:  2016-06-13       Impact factor: 20.096

9.  Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease.

Authors:  Ludimila Cavalcante; Asim Amin; Jose Lutzky
Journal:  Cancer Manag Res       Date:  2015-01-19       Impact factor: 3.989

10.  Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review.

Authors:  Jawaher Ansari; Muhammad Ali; Ashraf Farrag; Arwa M Ali; Abdulaziz Alhamad
Journal:  Case Reports Immunol       Date:  2018-06-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.